Related references
Note: Only part of the references are listed.Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
Kalijn F. Bol et al.
ONCOIMMUNOLOGY (2016)
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2
Julia M. Greene et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Lessons learned from cancer vaccine trials and target antigen choice
Lisa H. Butterfield
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
Kalijn F. Bol et al.
CLINICAL CANCER RESEARCH (2016)
Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer
Zibing Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Daniel Delitto et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives
Joao Constantino et al.
TRANSLATIONAL RESEARCH (2016)
Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation
Angus W. Thomson et al.
FRONTIERS IN IMMUNOLOGY (2016)
Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
Hai-Bo Xi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
Jeong-Hoon Lee et al.
BRITISH JOURNAL OF CANCER (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
Shuhei Mayanagi et al.
CANCER SCIENCE (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Advances in the management of gastrointestinal cancers-an upcoming role of immune checkpoint blockade
Gaurav Goel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
Gaurav Goel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
Alexander M. Lesokhin et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift
Anna L. de Goede et al.
VACCINE (2015)
New targeted therapies in pancreatic cancer
Andrada Seicean et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
Michal Podrazil et al.
ONCOTARGET (2015)
Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients
Sara Nava et al.
STEM CELLS TRANSLATIONAL MEDICINE (2015)
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
Soledad Mac Keon et al.
FRONTIERS IN IMMUNOLOGY (2015)
Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection
Aintzane Zabaleta et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2015)
Vaccine adjuvant uses of poly-IC and derivatives
Karen Ao Martins et al.
EXPERT REVIEW OF VACCINES (2015)
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
Yue Zhang et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2015)
Immune Therapy in Pancreatic Cancer: Now and the Future?
Yue Zhang et al.
REVIEWS ON RECENT CLINICAL TRIALS (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
Marion Subklewe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Davide Melisi et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Promising new therapies in advanced pancreatic adenocarcinomas
Madappa Kundranda et al.
FUTURE ONCOLOGY (2014)
Dendritic Cell-Derived Exosomes as Immunotherapies in the Fight against Cancer
Jonathan M. Pitt et al.
JOURNAL OF IMMUNOLOGY (2014)
Clinical use of dendritic cells for cancer therapy
Sebastien Anguille et al.
LANCET ONCOLOGY (2014)
Recent advances and new opportunities for targeting human dendritic cells in situ
Madhav V. Dhodapkar et al.
ONCOIMMUNOLOGY (2014)
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
Hirokazu Matsushita et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Inflammatory networks and immune surveillance of pancreatic carcinoma
Robert H. Vonderheide et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells
Philip J. Vernon et al.
JOURNAL OF IMMUNOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
Lisa H. Butterfield
FRONTIERS IN IMMUNOLOGY (2013)
Decisions About Dendritic Cells: Past, Present, and Future
Ralph M. Steinman
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Cancer immunotherapy via dendritic cells
Karolina Palucka et al.
NATURE REVIEWS CANCER (2012)
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
Robert M. Prins et al.
CLINICAL CANCER RESEARCH (2011)
Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
Karolina Palucka et al.
IMMUNITY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
Mohamed L. Salem et al.
JOURNAL OF IMMUNOLOGY (2009)
Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals
Vaios Karanikas et al.
CLINICAL IMMUNOLOGY (2008)
Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide
Irini Bolonaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Measures of response: RECIST, WHO, and new alternatives
C. Carl Jaffe
JOURNAL OF CLINICAL ONCOLOGY (2006)
Measuring response in a post-RECIST world: from black and white to shades of grey
LC Michaelis et al.
NATURE REVIEWS CANCER (2006)
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
J Babatz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin
K Otto et al.
VACCINE (2005)
Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2
Jian-Guo Qiao et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocyte's and mediates lysis of tumor cells
J Hernández et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy
A Scardino et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
